Upfront FOLFOXIRI Plus Bevacizumab with or Without Atezolizumab in the Treatment of Patients with Metastatic Colorectal Cancer (ATEZOTRIBE): A Multicentre, Open-Label, Phase 2, Randomised Controlled Trial by GONO

医学 贝伐单抗 阿替唑单抗 福尔菲里 伊立替康 内科学 奥沙利铂 结直肠癌 肿瘤科 临床研究阶段 胃肠病学 外科 化疗 癌症 彭布罗利珠单抗 免疫疗法
作者
Carlotta Antoniotti,Daniele Rossini,Filippo Pietrantonio,Aurélie Catteau,Lisa Salvatore,Sara Lonardi,Isabelle Boquet,Stefano Tamberi,Federica Marmorino,Roberto Moretto,Margherita Ambrosini,Emiliano Tamburini,Giampaolo Tortora,Alessandro Passardi,Francesca Bergamo,Alboukadel Kassambara,Thomas Sbarrato,Federica Morano,Giuliana Ritorto,Beatrice Borelli
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:23 (7): 876-887 被引量:311
标识
DOI:10.1016/s1470-2045(22)00274-1
摘要

Immune checkpoint inhibitors have not shown clinical benefit to patients with metastatic colorectal cancer who had proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumours in previous studies. Both an active combination chemotherapy (FOLFOXIRI; fluorouracil, leucovorin, oxaliplatin, and irinotecan) and bevacizumab seem able to increase the immunogenicity of pMMR or MSS tumours. We aimed to provide preliminary evidence of benefit from the addition of the anti-PD-L1 agent atezolizumab to first-line FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer.AtezoTRIBE was a multicentre, open-label, randomised, controlled, phase 2 study of patients (aged 18-70 years with an Eastern Cooperative Oncology Group [ECOG] performance status of 0-2 and aged 71-75 years with an ECOG performance status of 0) with histologically confirmed, unresectable, previously untreated metastatic colorectal cancer and adequate organ function, who were recruited from 22 oncology centres in Italy. Patients were stratified according to centre, ECOG performance status, primary tumour site, and previous adjuvant therapy. A randomisation system incorporating a minimisation algorithm randomly assigned (1:2) patients via a masked web-based allocation procedure to two groups: the control group received first-line FOLFOXIRI (intravenous 165 mg/m2 irinotecan, 85 mg/m2 oxaliplatin, 200 mg/m2 leucovorin, and 3200 mg/m2 fluorouracil as a 48 h infusion) plus bevacizumab (5 mg/kg intravenously), and the atezolizumab group received the same regimen plus atezolizumab (840 mg intravenously). Combination treatments were administered up to eight 14-day cycles followed by maintenance with fluorouracil and leucovorin plus bevacizumab with or without atezolizumab, according to randomisation group, until disease progression, unacceptable adverse events, or consent withdrawal. The primary endpoint was progression-free survival, analysed by the intention-to-treat principle. Safety was assessed in patients who received at least one dose of the study treatment. The study recruitment is completed. The trial is registered with Clinicaltrials.gov, NCT03721653.Between Nov 30, 2018, and Feb 26, 2020, 218 patients were randomly assigned and received treatment (73 in the control group and 145 in the atezolizumab group). At the data cutoff (Aug 1, 2021), median follow-up was 19·9 months (IQR 17·3-23·9). Median progression-free survival was 13·1 months (80% CI 12·5-13·8) in the atezolizumab group and 11·5 months (10·0-12·6) in the control group (hazard ratio [HR] 0·69 [80% CI 0·56-0·85]; p=0·012; adjusted HR 0·70 [80% CI 0·57-0·87]; log-rank test p=0·018). The most frequent all-cause grade 3-4 adverse events were neutropenia (59 [42%] of 142 patients in the atezolizumab group vs 26 [36%] of 72 patients in the control group), diarrhoea (21 [15%] vs nine [13%]), and febrile neutropenia (14 [10%] vs seven [10%]). Serious adverse events were reported in 39 (27%) patients in the atezolizumab group and in 19 (26%) patients in the control group. Two (1%) treatment-related deaths (due to acute myocardial infarction and bronchopulmonary haemorrhage) were reported in the atezolizumab group; none were reported in the control group.The addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab is safe and improved progression-free survival in patients with previously untreated metastatic colorectal cancer.GONO Foundation, ARCO Foundation, F Hoffmann-La Roche, and Roche.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
一朵荷花半点红完成签到,获得积分20
刚刚
wjx发布了新的文献求助10
刚刚
刚刚
刚刚
Juvenilesy的应助被从容寻芹采纳,获得10
刚刚
入司的应助被Wen采纳,获得10
刚刚
Mine发布了新的文献求助20
1秒前
1秒前
1秒前
2秒前
2秒前
搜集达人的应助被hhhhzzzz采纳,获得10
3秒前
小橘子发布了新的文献求助20
3秒前
zaq66996发布了新的文献求助10
3秒前
apingsence发布了新的文献求助10
4秒前
4秒前
5秒前
充电宝的应助被xinnnnnn采纳,获得10
5秒前
单薄天荷发布了新的文献求助10
5秒前
5秒前
随机截距发布了新的文献求助10
5秒前
sonjsnd完成签到,获得积分10
6秒前
6秒前
任娜发布了新的文献求助10
6秒前
小木子完成签到,获得积分10
6秒前
可悲的小孩完成签到,获得积分10
7秒前
科研小白完成签到,获得积分10
7秒前
1210xi完成签到,获得积分10
8秒前
牙牙完成签到,获得积分10
8秒前
1arkspur发布了新的文献求助10
8秒前
8秒前
Joy发布了新的文献求助10
8秒前
8秒前
周周发布了新的文献求助10
9秒前
zmc完成签到,获得积分10
9秒前
乐乐的应助被kevin采纳,获得10
10秒前
赘婿的应助被单薄天荷采纳,获得10
10秒前
wang完成签到,获得积分10
10秒前
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182602
求助须知:如何正确求助?哪些是违规求助? 9572033
关于积分的说明 21821767
捐赠科研通 7779061
什么是DOI,文献DOI怎么找? 3433684
关于科研通互助平台的介绍 2557863
邀请新用户注册赠送积分活动 2479732